BioNTech experiences constructive knowledge for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging knowledge from a part II cohort of their international medical trial evaluating the efficacy of trastuzumab pamirtecan (BNT323/DB-1303) within the therapy of superior endometrial most cancers expressing human epidermal progress issue receptor 2 (HER2).
This cohort is a part of a part I/IIa examine designed to evaluate each the protection and tolerability of the antibody-drug conjugate (ADC) trastuzumab pamirtecan in varied strong tumors.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra info
Key major endpoints, together with goal response price and security, have been measured, with a specific deal with sufferers with confirmed HER2 standing by way of retrospective central testing.
Secondary endpoints collected knowledge on illness management charges, progression-free survival, and general survival.
The Section II cohort evaluation included 145 sufferers whose situation worsened after preliminary chemotherapy, with or with out prior checkpoint inhibitor remedy.
Trastuzumab pamirtecan, a third-generation topoisomerase-1 inhibitor-based remedy, demonstrated an appropriate security profile for sufferers in any respect ranges of HER2 expression.
The first efficacy endpoint was met, with a confirmed goal response price of 49.3% amongst 73 sufferers who had obtained prior checkpoint inhibitor remedy and had their HER2 standing centrally confirmed.
In all centrally examined sufferers, the response price was 47.9%, with a median progression-free survival of 8.1 months.
Outcomes from 143 sufferers examined regionally for HER2 standing confirmed a confirmed response price of 44.1%, demonstrating constant antitumor exercise throughout expression ranges.
Notably, larger HER2 expression correlated with a extra vital response price, akin to 73.1% in sufferers with an Immunohistochemistry Rating 3+ (IHC3+). The median length of response for the whole cohort was 10.3 months.
Co-founder and Chief Doctor of BioNTech, Professor Özlem Türeci, stated: “These constructive ends in sufferers with endometrial most cancers, together with these with decrease HER2 expression ranges, assist the potential of trastuzumab pamirtecan.
“We proceed to develop trastuzumab pamirtecan, each as a monotherapy and as a novel therapy mixture method, with the purpose of addressing the numerous unmet medical wants within the therapy of sufferers with HER2-induced tumors.”
Widespread unwanted effects noticed have been delicate nausea, anemia, decreased platelet rely and fatigue.
Extra severe adversarial occasions of grade 3 or larger affected 46.9% of sufferers, with interstitial lung illness or pneumonitis occurring in 4.8% of circumstances.
BioNTech and DualityBio anticipate to file a biologics licensing utility this yr, relying on suggestions from the U.S. Meals and Drug Administration (FDA).
In December 2025, Bristol Myers Squibb and BioNTech’s pumitamig confirmed promising efficacy and security in a mid-stage examine in triple- and second-line triple-negative breast most cancers.
